Latest Loss Reduction News

Acrux Limited reported a 46% revenue increase to $6.6 million in FY26, driven by US generic product royalties and licensing milestones, while narrowing its net loss by 90%. The company is pivoting towards developing a female testosterone therapy with encouraging Phase II data and active regulatory engagement.

Camplify Holdings slashed its net loss by 95% in FY26, posting a second-half profit driven by cost cuts and the MyWay Mutual insurance launch, setting a foundation for growth in FY27.

Genetic Signatures narrowed its FY2026 net loss by 30% to $14 million amid a strategic overhaul, signing a key 10-year supply deal with Denmark’s Hvidovre Hospital and resetting its US market approach.

Blackpearl Group reported a 95% year-on-year ARR increase to $27.2 million in Q1 FY27, alongside a strategic shift to higher-quality revenue and a clear path to reducing EBITDAF losses through FY27. The company also launched its Platform as a Service offering ahead of schedule, underpinning its evolving revenue model.

Me Today has raised its full-year revenue forecast to over NZD 7.4 million, driven by strong domestic sales and a new exclusive distribution deal in Southeast Asia. The nutritional supplements company also expects a 25% reduction in EBITDA loss, reflecting tighter cost control amid ongoing product innovation.

IDT Australia is poised for its strongest FY26 finish since its transformation began, forecasting a dramatic narrowing of EBITDA losses and revenue growth driven by strategic partnerships and operational upgrades.

DigitalX Limited closed the March 2026 quarter with A$59.5 million in liquid assets, unveiling a A$30 million strategic investment program and delivering record revenue from its Sell My Shares platform, signalling a pivot towards disciplined capital deployment and sustainable growth.

Vectus Biosystems has completed the sale of its VB4-P5 renal fibrosis compound to Canadian biotech XORTX, receiving a near 10% equity stake and warrants. This move aligns with Vectus’ strategy to develop drug candidates to a stage attractive to partners while focusing on its lead compound VB0004.

Epsilon Healthcare Limited has reported a robust recovery in 2025, with revenue climbing 68% to $9.39 million and net losses shrinking by 63%, driven by growth in contract manufacturing and a new pharmacy division.

DigitalX Limited reported a narrower half-year loss and increased revenues, underpinned by a strategic pivot to a Bitcoin-first treasury model and operational cost discipline.

Dataworks Group Limited reported a significant reduction in its half-year loss alongside a major contract extension in Ontario, marking a pivotal shift to positive cash flow.

Spenda Limited reported a significant reduction in its half-year net loss to $6 million, alongside a doubling of payment transaction volumes, as it restructures leadership and refocuses its core software and payments products.